An Open Label Window of Opportunity Phase II Study of the FAK Inhibitor Defactinib VS-6063 in Participants With Surgical Resectable Malignant Pleural Mesothelioma.
Latest Information Update: 22 Feb 2024
At a glance
- Drugs Defactinib (Primary)
- Indications Malignant-mesothelioma
- Focus Biomarker; Pharmacodynamics
- Sponsors Verastem Oncology
- 18 Oct 2019 Status changed from recruiting to discontinued.
- 11 Oct 2018 Planned End Date changed from 1 Sep 2018 to 1 Sep 2019.
- 11 Oct 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Sep 2019.